Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.39 |
| ▸ | HTR3A | P46098 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | DEGS1 | O15121 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16368736 | 1.00 | SLC9A1 (0.46) | SLC9A1MAPTKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL10177682 | 1.00 | SLC9A1 (0.46) | SLC9A1MAPTKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL716700 | 0.82 | AKR1C3 (0.52) | SLC9A1MAPTHSD17B10ALDH1A1POLB | |
| SCHEMBL2688880 | 0.80 | AKR1C3 (0.58) | SLC9A1MAPTHSD17B10ALDH1A1GAA | |
| SCHEMBL28329004 | 0.78 | SLC9A1 (0.44) | SLC9A1MAPTKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL22209881 | 0.78 | SLC9A1 (0.44) | SLC9A1MAPTKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL7281211 | 0.77 | PAX8 (0.41) | ALDH1A1 | |
| SCHEMBL11660635 | 0.77 | SLC6A3 (0.48) | SMN1; SMN2L3MBTL1 | |
| Carbamic Acid SCHEMBL1569088 | 0.76 | IDO1 (0.49) | SLC9A1MAPTKMT2AHSD17B10ALDH1A1 | |
| SCHEMBL7976148 | 0.75 | ALOX5 (0.47) | SLC9A1MAPTKMT2AHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-9067951-B2 | Process and intermediates for the production of CCR2 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-06-30 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-13 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-8835440-B2 | Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-09-16 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053164-A1 | CYCLIC PYRIMIDIN-4-CARBOXAMIDES AS CCR2 RECEPTOR ANTAGONISTS FOR TREATMENT OF INFLAMMATION, ASTHMA AND COPD | CCR2, CCR1, CCR5 | SLC9A1 2441/4885MAPT 4507/4885KMT2A 2199/4885 |
| US-20140336374-A1 | PROCESS AND INTERMEDIATES FOR THE PRODUCTION OF CCR2 ANTAGONISTS | CCR2, CCR5, CCR1 | SLC9A1 4747/4885MAPT 4651/4885KMT2A 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.